FindTrial
Sign In

To test the number of Circulating Tumor Cells (CTC) captured by the OncoDiscover Liquid Biopsy in peripheral blood samples of Head and Neck cancer patients.

A clinical trial to test the number of Circulating Tumor Cells (CTC) captured by the OncoDiscover Liquid Biopsy in peripheral blood samples of Head and Neck cancer patients. (CTCSEN)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/03/012905
Enrollment
100
Registered
2018-03-27
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Confirmed diagnosis of stage 2-4 Head and Neck Cancer

Interventions

None listed

Sponsors

Actorius Innovations and Research Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Males or Females. 2. Age > 18 years of age. 3. Written informed consent obtained. • Confirmed diagnosis of stage 2-4 Head and Neck, (OR) no prior history of cancer. • Stage 2-4 treatment naive, metastatic, secondary, and recurrent cancer patients. • Able to undergo blood collection prior to initiation of chemotherapy treatment, (OR) able to provide blood sample if subject is a non-cancer control subject.

Exclusion criteria

Exclusion criteria: 1. Patients unable to understand the research protocol and/or provide informed consent. 2. Patients with known immunodeficiency, or pregnancy.

Design outcomes

Primary

MeasureTime frame
The number of circulating tumor cells (CTCs) per milliliter of whole blood. Reported unit of measure will be the number of CTCs/milliliter.Timepoint: 12 months—

Secondary

MeasureTime frame
NATimepoint: NA—

Countries

India

Contacts

Public ContactAravindan Vasudevan

Actorius Innovations and Research Pvt Ltd

jayant@actorius.co.in919920526627

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 18, 2026